Table 1.
Characteristics of included studies
| Reference | Year of publication | Sample size (control/intervention) | Country/population | Intervention (name and daily dose) | Duration of study | Type of study | Clinical outcomes |
|---|---|---|---|---|---|---|---|
| Muresanu et al29 | 2015 | 4,787/615 | Romania/patients with mild, moderate, or severe TBI | Cerebrolysin 20 or 30 mL | 10 or 30 days | Cohort study | GOS and mRS |
| Wong et al30 | 2005 | 21/21 | China/patients with moderate or severe TBI | Cerebrolysin 50 mL | 6 months | Cohort study | GOS and mRS |
| Khalili et al32 | 2017 | 64/65 | Iran/patients with severe TBI | Cerebrolysin 10 mL | 6 months | Cohort study | GOS and mRS |
| Asghari et al31 | 2014 | 28/25 | Iran/patients with moderate or severe TBI | Cerebrolysin 10 mL | 10 days | Randomized clinical trial | GOS and mRS |
| Alvarez et al23 | 2008 | 20/39 | Spain/patients with mild or severe TBI | Cerebrolysin 10 mL | 12 months | Cohort study | GOS and mRS |
Abbreviations: GOS, Glasgow Outcome Scale; mRS, modified Rankin Scale; TBI, traumatic brain injury.